People

Alaa Halawa is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Director. This is an advisory or cohort network affiliation, rather than a firm employee position.

Founding partner of 3E Bioventures Capital, investing in healthcare and the intersection of medical and information technologies. Previously led healthcare investment at Kaiwu Capital and CRCI Capital, co-founded Shenogen Pharma and worked at McKinsey. Holds a Cornell bachelor's degree, a Harvard Master of Medical Sciences and immunology PhD, and a CKGSB EMBA.

Myrobalan PET imaging adviser and Harvard Medical School radiology researcher at Massachusetts General Hospital. Develops small-molecule PET radioligands and immunoPET approaches for neurological and demyelinating diseases. Holds a University of Chicago chemistry PhD.

Myrobalan clinical adviser for neuro-ophthalmology, also known as Yin Allison Liu. UC Davis neuro-ophthalmology researcher studying ocular biomarkers for neurological and neurodegenerative conditions, with training in cancer immunotherapy, child neurology and neuro-ophthalmology.

Current primary B Capital biography reviewed October8,2026: Karen Page is a General Partner and Board Partner at B Capital. As a Board Partner, she collaborates with portfolio company leadership, B Capital’s investment team and the firm’s network of advisors to provide best-in-class strategic guidance, governance expertise, and hands-on operating support to help companies scale and succeed. At B Capital, she has invested in and/or serves on the board of early-stage and growth companies such as Overstory, Pendo, Clari, Highspot, Centivo, Isaac Health, and Kandji. Prior to joining B Capital, Karen made significant contributions to industry giants like Apple, where she spearheaded the commercial channel, strategic partnerships and key mobility initiatives. As one of the founding executives at Box, she played a pivotal role in shaping the company’s go-to-market strategy, forging partnerships, establishing Box.org and leading the Industry Verticals team. During her tenure, Box grew from zero revenue to over a billion-dollar valuation and successfully went public in 2015. Karen earned a BS from Towson University and an MS in Advanced Behavioral Science and Organizational Development from Johns Hopkins Carey Business School. She is based in San Francisco.

Craig Fox is listed as Operating Partner, Life Sciences by Oxford Science Enterprises. Current public directory reviewed October7,2026.

Myrobalan clinical adviser for neuro-ophthalmology and a UC Davis ophthalmology clinician-scientist. Studies retinal diseases, ocular imaging, gene editing and delivery. Holds Harvard MD-PhD degrees, with residency at Massachusetts Eye and Ear and fellowship training at Duke.

Myrobalan biomarker adviser and translational neuroscience scientist. Worked on neurological drug development at Biogen and Elan and advises on industry-academic collaborations. Holds a Yale molecular biophysics and biochemistry PhD.

Myrobalan clinical adviser for multiple sclerosis and neuromyelitis optica. Neurologist at Massachusetts General Hospital and Harvard Medical School specializing in neuroimmunology and MS care. Trained at the University of South Dakota and Washington University in St. Louis.

Myrobalan scientific adviser and Northwestern University neurology professor. Studies oligodendrocytes, myelin biology and neurological disorders involving demyelination, including multiple sclerosis, to develop approaches to myelin repair.

Myrobalan clinical adviser for multiple sclerosis and a University of Freiburg neurology professor. Researches inflammatory neurodegeneration, immune regulation and monitoring of MS and its treatment. Previously led neurology at the University of Münster.

Myrobalan clinical adviser for ALS and a neurologist at The Neuro in Montreal. Leads ALS care and research programs and works on clinical trial design for rare neurological and motor neuron diseases. Earned her medical degree at Memorial University of Newfoundland.

Myrobalan scientific adviser and Harvard stem cell and regenerative biology researcher. Studies neurodegeneration, neuromuscular regeneration and brain aging, with translational neuroscience experience in biotechnology and academia. Holds a Rockefeller University neuroscience PhD.

Myrobalan board adviser with biotechnology leadership, fundraising and public offering experience. Previously led Curis and held business development roles at the Jackson Laboratory and Gene Logic. Holds a George Washington University law degree.

Myrobalan board adviser and biotechnology executive. Previously president and CEO of Curis and ACT Biotech, chief scientific officer at Sagres Discovery and a vice president at Onyx Pharmaceuticals. Holds a Kansas State University microbiology PhD.

Myrobalan board adviser and healthcare finance executive. Previously CFO at Constellation Pharmaceuticals, Parexel, Inotek and Aton, with experience in company transformation, public offerings and acquisitions. Its current directory lists an adviser role following a 2024 director appointment.

Myrobalan board adviser and biotechnology executive. Former Epizyme CEO and TESARO chief commercial officer, with earlier leadership experience at Millennium Pharmaceuticals, McKesson, Roche and Knoll. Previously appointed to Myrobalan's board of directors in 2024; its current directory lists him as an adviser.

Myrobalan board member and 3E Bioventures Capital partner. Previously worked in pharmaceutical R&D at Novartis, Roche and GlaxoSmithKline. Holds a Fudan University physics degree and a New York University biochemistry PhD.

Myrobalan board member and managing director at Guanzi Private Equity Fund Management in Hangzhou. Previously a managing director at CICC Capital. Holds a University of Illinois Urbana-Champaign finance MS and a Peking University bachelor's degree.

Myrobalan board member and Co-win Ventures managing partner who established its healthcare practice. Previously a BCG consultant and Omaha Capital senior investment manager. Holds a Peking Union Medical College MD and a Johns Hopkins PhD. Distinct from the Curie.Bio structural biology scientist with the same name.

Myrobalan consultant leading chemistry, manufacturing and controls. Technical operations executive with small-molecule development experience at Curis, Imara and Ziopharm. Holds a Northeastern MBA and a Rochester Institute of Technology chemistry BS.

Myrobalan consultant leading global regulatory strategy. Regulatory and quality executive with experience at Alkermes, Palleon Pharmaceuticals and Biogen, covering small molecules, biologics and gene therapies. Holds a UC Berkeley organic chemistry PhD.

Myrobalan finance director and corporate controller, overseeing finance, accounting and operational matters. Previously worked at Putnam Investments and Poseidon Water. Holds a Suffolk University accounting master's degree and an economics BA from Shanghai University of International Business and Economics.

Myrobalan head of medicinal chemistry, leading chemistry across its portfolio. Previously developed small-molecule programs at Alantos, Hydra Biosciences, Mitobridge and Tango Therapeutics. Holds a SUNY Stony Brook organic chemistry PhD and a Peking University chemistry BS.

Myrobalan fractional chief medical officer and physician-scientist with translational and clinical neuroscience drug development experience. Previously chief medical officer at Cassava Sciences and ProMIS Neurosciences and a neuroscience clinical development leader at Pfizer.

Myrobalan chief scientific officer and neuroscience drug discovery leader. Previously led CNS biology at Alkermes, established translational cellular science capabilities at Biogen and worked on CNS discovery at Pfizer. Holds a University of Virginia neuroscience PhD and completed postdoctoral research at UCSF.

Myrobalan co-founder, CEO and board member. Drug development leader with prior R&D roles at Curis, TESARO/GSK and Constellation. Led translational work on ZEJULA and holds a Harvard Medical School PhD focused on neurodegeneration.

Myrobalan scientific co-founder and board member. MIT neuroscience professor and McGovern Institute researcher studying synaptic modulation and psychiatric disorders. Also works with the Broad Institute and co-founded companies including Rugen, NeuralGalaxy and Emugen.

AB Magnitude Ventures Group founding managing director and computational drug discovery scientist. A founding member of D. E. Shaw Research, he helped design the Anton molecular dynamics supercomputer and developed simulation algorithms for structural biology and drug discovery. Holds a computer science master's degree and a biophysics PhD from Drexel University. Also a board member at Myrobalan Therapeutics.

Christopher Eso is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as VP, CSH Strategy, Growth & Business Development Medtronic. This is an advisory or cohort network affiliation, rather than a firm employee position.

Andrew Cleeland advises ClavystBio and is CEO of Fogarty Innovation. He previously led the medical-device companies Ardian and Twelve, both subsequently acquired by Medtronic, and later led Medtronic’s transcatheter mitral-valve business.

Healthcare venture investor listed as an independent director of BioScience Managers. Her published career includes Domain Associates, Rothschild Asset Management, Cephalon and Eastman Kodak investment/corporate-development work. Holds mathematics and finance degrees from Rochester. Outside boards in the older biography are career context rather than independently verified current appointments.

ArrePath board member and Boehringer Ingelheim Venture Fund investment manager in the United States. Joined BIVF in 2026 after a decade of drug discovery and oncology R&D at Boehringer Ingelheim. Holds a biology PhD from the Max Planck Institute for Multidisciplinary Sciences, with postdoctoral research at IMBA in Vienna.

ArrePath board member and Innospark Ventures managing director. Entrepreneur and investor with expertise in AI, natural language understanding and computational algorithms. Founded companies including eCredit, Corporate Fundamentals and Rage Frameworks, and previously taught at Northeastern University. Founder and Managing Director of Innospark Ventures, focused on applied AI and early-stage scientific technology. His entrepreneurial background includes eCredit, Corporate Fundamentals and Rage Frameworks. His primary biography describes AI, natural-language understanding and computational research, a doctorate from the University of Cincinnati and undergraduate study at Delhi University.

ArrePath board chair and physician-scientist with biotechnology company leadership experience. Previously led AZURNA Therapeutics, Laronde and Vividion Therapeutics and held R&D leadership roles at Johnson & Johnson. Earned an MD from the University of Buenos Aires.

ArrePath founder, scientific advisory board chair and board member. Princeton professor of biology and molecular biology researching bacterial cell biology and antibiotic development with quantitative and computational methods. Educated at MIT and UCSF, with postdoctoral research at Stanford.

ArrePath chief technology officer leading AI/ML strategy and scientific data infrastructure. Built the company's AI/ML platform as its second employee. Previously led data science at Zymergen and directed the Nikon Imaging Center at UCSF. Holds a UCSF biophysics PhD and a Princeton chemistry BA.

ArrePath chief scientific officer leading scientific strategy and drug discovery programs. Previously held R&D leadership roles at Entasis Therapeutics and Design Therapeutics, and worked at AstraZeneca, Pfizer, Merck and Eli Lilly. Earned a PhD in biochemistry and molecular biology from the University of Chicago.

ArrePath president, CEO and board member. Previously chief strategy officer at AN2 Therapeutics, with drug development and corporate development experience at Achaogen, Cerexa and Theravance BioPharma. Holds an MBA from UC Berkeley and a BS in cell and molecular biology from San Francisco State.

Becca Shmukler is a Partner at Laerdal Million Lives Fund, with healthcare-industry experience at the Advisory Board Company, Castlight Health and Rock Health. Novocuff’s July2024 issuer announcement names her board appointment; current board membership is not independently republished on its current team page.

Physician and Faro AI co-founder. Helped establish the company's platform for digital clinical study design and authoring.

Financial Controller at Faro AI, a company developing AI and structured data infrastructure for clinical development.

SVP, Customer at Faro AI, a company developing AI and structured data infrastructure for clinical development.

Board Chair at Faro AI, a company developing AI and structured data infrastructure for clinical development. San Francisco operating partner at Polaris investing in healthcare services and products. The current manager biography confirms his Faro Health/Faro AI board affiliation and work with Foresight Mental Health and UpDoc. Formerly CEO of oDesk.

Chief Commercial Officer at Faro AI, a company developing AI and structured data infrastructure for clinical development.

Faro AI co-founder and chief executive officer, developing structured data and AI infrastructure for clinical development.

Peter D. Parker is published as a Mission Bay Capital venture partner in its undated directory. The biography describes his historical managing general partner affiliation with BioInnovation Capital, his cofounding of Cambridge BioLabs and LabCentral with Johannes Fruehauf, and earlier life-science investing at Ampersand Capital Partners. He was President and CEO of Cequent Pharmaceuticals from2006to2010 and studied at Columbia University. The undated BioInnovation title is historical context rather than proof of a currently independent adviser; he is distinct from unrelated Peter Parker names.

Johannes Fruehauf, MD, is a QurAlis director and co-founder of Mission BioCapital, LabCentral and BioLabs. His background combines medical and entrepreneurial biotechnology work, with doctoral training in Heidelberg and postdoctoral research at Beth Israel Deaconess/Harvard.

Linda Eng is published as Mission Bay Capital office manager, supporting investment tracking, meetings and administration. Its undated biography also describes her business-management work at the QB3@953/MBC BioLabs laboratory incubator and earlier UCSF translational research programme management. She helped the venture fund during its formation while assisting Douglas Crawford, and later coordinated multicentre cancer-research activities. Historical outside project budgets are not venture fund capital or personal investments.

Douglas Crawford is a scientist and life-science investor with a UCSF biochemistry PhD. Mission Bay Capital publishes him as managing director; March2026 ADV confirms Douglas Kingsley Crawford as managing director of the original manager and managing member of the FundII/FundIII advisers. He founded and manages the MBC BioLabs shared-laboratory network and the published biography also identifies his Mission BioCapital managing partner affiliation. Published laboratory and portfolio-company totals are historical programme claims, not personally invested capital.

Robert Blazej is a biotechnology entrepreneur and investor published as a Mission Bay Capital partner. March2026 Awesome Enablers ADV corroborates Robert Glenn Blazej as principal of the FundIII adviser. He previously directed digital biotechnology and global scouting at Novozymes and co-founded Allopartis Biotechnologies, acquired by Novozymes in2013. His2006 joint UC Berkeley/UCSF bioengineering doctorate focused on microfluidic DNA-sequencing systems. External MBC BioLabs and Mission BioCapital affiliations remain separate.

K. Ranga Krishnan is a ClavystBio director and senior adviser to the Rush University System for Health. He previously served as Rush Medical College dean and Rush’s chief executive, and earlier led Duke-NUS Graduate Medical School Singapore.

Kevin Lalande is listed by Santé Ventures as Founding Managing Director & Chief Investment Officer. Co-founded the firm in 2006 after Austin Ventures and McKinsey; trained in electrical engineering, business and artificial intelligence.

Publicly named PTX Capital teammate. Her precise investment or operating title is not disclosed in the cited primary source.

Physician publicly named as a PTX Capital teammate by investment analyst Daniel Antov. His precise investment or operating title is not disclosed in the cited primary source.

PTX Capital investment analyst and Johns Hopkins biomedical engineering PhD researcher. His research includes biomaterials and drug delivery, and Johns Hopkins announced his NSF Graduate Research Fellowship in 2025.

PTX Capital venture partner and Johns Hopkins ophthalmologist working on AI and precision medicine. Founding director of the Wilmer Precision Ophthalmology Center of Excellence and publicly named PTX teammate.

PTX Capital founder and managing partner, also known as Matt Hellauer. Previously worked at Allen & Company from 2011 to 2021. Studied mathematics at Georgetown and earned an MBA at Harvard Business School.

Partner at Hoxton Ventures with software industry and venture investing experience.

Toyin Ajayi is co-founder and part-time gp at Coalition Operators. Alongside her work at Coalition, Toyin is the co-founder and CEO of Cityblock Health, a multibillion-dollar company delivering high-quality care to the most marginalized populations. She’s a physician by training, and has spent her career building solutions for people who’ve been left behind by the U.S. healthcare system. Toyin shares her hard-won insights on building in regulated industries and scaling complex teams and businesses. She’s especially helpful to founders navigating healthcare, education, and all things tech-enabled services. Outside company titles are attributed to the firm’s published biography, not automatically changed on external organizations.

Nell Brennan is director of finance at Valia Ventures, as listed in the firm's current team directory.

Riley Rodgers is venture partner at Valia Ventures, as listed in the firm's current team directory.

Omar Sebai is principal at Valia Ventures, as listed in the firm's current team directory.

Khaled Jalanbo is managing partner at Valia Ventures, as listed in the firm's current team directory.

Inner Logic co-founder and chief robotics officer, and Johns Hopkins mechanical engineering associate professor. Leads research on image-guided interventions and autonomous surgical robots, including the Smart Tissue Autonomous Robot's animal-model research.

Inner Logic co-founder and chief technology officer, and Johns Hopkins computer science associate professor. Researches computer vision, AI-assisted medicine, simulation, mixed reality and medical robotics.

Inner Logic co-founder and chief executive officer, trained in medicine and neurosurgery at Dartmouth and Johns Hopkins. Builds AI and simulation infrastructure for procedural devices and surgical autonomy; also holds an MBA from Johns Hopkins Carey Business School.

Defined investor with experience in AI infrastructure, biotechnology, climate technology and portfolio operations. Previously worked in product marketing at Rafay Systems, helping commercialize GPU cloud and distributed AI inference infrastructure.

Defined venture partner with experience building investment practices at Prologis Ventures and GreatPoint Ventures. Founder of Public School Ventures and Stresswood and co-host of the Swimming with Allocators venture capital podcast.

Defined operating and venture partner and technology entrepreneur. Founded or co-founded startups including Visio, Netbot, Qpass and Medio; also a partner at Threshold Ventures. Supports founders on product strategy, commercial development and organizational growth.

Defined venture partner with more than 25 years of technology investment and company-building experience. Previously a general partner at Rho Canada Ventures, with investment leadership experience at 3i Group and BDC Capital. Also co-founder and managing partner of True North Fund.

Builds neuroscience research partnerships between academia and industry.

Chairman of Ovid Therapeutics’ Scientific and Clinical Advisory Board. A biomedical engineer and MIT Institute Professor known for drug delivery and tissue engineering research, and a founder of biotechnology companies. Robert S. Langer ScD is PureTech’s co-founder, non-executive director and R&D Committee member, and MIT’s David H. Koch Institute Professor. His biomedical engineering research covers drug delivery and tissue engineering, with extensive patents and licensing. He studied chemical engineering at Cornell and MIT; his existing Ovid scientific advisory identity and portrait are preserved. Robert Langer is published by aMoon as External Adviser. MIT biomedical engineering professor whose research concerns drug delivery, biotechnology and tissue engineering. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.